Beta-D-N4-hydroxycytidine (NHC) for the Treatment of SARS-CoV-2

Creative Biolabs has long-term devoted to the development and application of antiviral drug discovery. In response to SARS-CoV-2 infections, we are pleased to use our extensive experience and advanced platform to offer the best services and the most qualified products to satisfy each demand from our customers.

Introduction of SARS-CoV-2

SARS-CoV-2, a newly identified coronavirus, has been spreading in China and has now reached multiple in other countries. Coronaviruses are a large family of viruses common in a variety of animals and sometimes can infect humans, such as SARS, MERS, and the SARS-CoV-2 now. The genetic analyses showed that SARS-CoV-2 emerged from a virus related to SARS and the possible symptoms include fever, cough, and shortness of breath. Based on the previous research results, these symptoms of SARS-CoV-2 may appear in 2-14 days after exposure. In this situation, public health officials, scientists, researchers, media and the public should take this current SARS-CoV-2 outbreak seriously and monitor it. As a professional drug discovery-related services provider, Creative Biolabs now can provide a series of services for our customers all over the world.

Fig.1 Novel coronavirus (2019-nCoV).

Beta-D-N4-hydroxycytidine (NHC) Against Viruses

Beta-D-N4-hydroxycytidine (NHC), with the CAS No. 3258-02-4, is a base-modified ribonucleoside analogue recognized as a potent and selective antiviral candidate. NHC presents efficient antiviral activity against a variety of viruses, which include but are not limited to Chikungunya Virus (CHIKV), Venezuelan equine encephalitis Virus (VEEV), and Hepatitis C Virus (HCV).

Till now, the antiviral mechanism of action of NHC is still not completely understood. Some studies have shown that its nucleotide may act as a weak alternative substrate for CTP in the virus RNA polymerization reaction. In this case, insert the MHC-Monophosphate into viral RNA may change the thermodynamics of regulatory secondary structures. In conclusion, NHC might be a new efficient antiviral agent for the treatment of RNA virus infections. However, based on the stability studies in human and monkey whole blood, it showed that NHC might not persist enough time in plasma at a physiological pH and temperature to deliver significant antiviral levels of NHC into HCV-infected liver cells. In addition, a novel approach to prevent the oxidation or reduction of NHC should be developed for advancing this nucleoside to the clinic. As NHC might be an efficient drug in response to the SARS-CoV-2 outbreak, Creative Biolabs now can provide the further assays for our clients and develop novel antiviral drugs against SARS-CoV-2.

Fig.2 Structure of Beta-D-N4-hydroxycytidine (NHC).

Creative Biolabs has been a long-term expert in the field of drug discovery. We are therefore confident in offering the best and most suitable service for our customer. To fill the gaps in this field, we would try our best to provide a customized proposal to meet your project requirements in the quality, timeline, and budget. If you are interested in our services, please do not hesitate to contact us for more details.

For Research Use Only. We do not provide direct services or products for patients.